Paratek Pharmaceuticals, a biopharmaceutical company, saw a 20% surge in its stock price following reports that it is a takeover target. According to Betaville Intelligence, a private equity firm is said to be the leading suitor. Paratek’s products include Nuzyra and Seysara, both antibiotics. Despite the surge in its stock price, Seeking Alpha’s Quant Rating views Paratek as a hold.
- Paratek Pharmaceuticals (NASDAQ:PRTK) is up 20% in Tuesday afternoon trading amid a report that the biopharma is a takeout target.
- Betaville Intelligence is reporting that those familiar with the situation say a private equity firm is the leading suitor.
- Paratek’s (PRTK) marketed products include the antibiotics Nuzyra (omadacycline) and Seysara (sarecycline).
- Seeking Alpha’s Quant Rating views Paratek (PRTK) as a hold.
Source: SeekingAlpha
